囊性纤维化患者抗常见多糖抗原抗体难以抑制补体杀菌
尽管抗CPA抗体普遍存在,仅1对血清-菌株显示补体抑制,且该菌株CPA表达显著高于其他菌株。结论提示清除遮蔽抗体治疗铜绿假单胞菌时,通常无需同时清除CPA特异性抗体。
要点
- 囊性纤维化患者中抗CPA抗体普遍存在,但仅极少数能抑制补体杀菌。
- 仅1株CPA高表达菌株的补体杀菌被抗CPA抗体以滴度依赖方式抑制。
- 清除遮蔽抗体治疗铜绿假单胞菌时,通常无需同时清除CPA特异性抗体。
核心结论
- 抗CPA抗体在囊性纤维化患者中普遍存在,但无法抑制大多数CPA表达菌株的补体 killing。
- 通过清除遮蔽抗体治疗铜绿假单胞菌时,通常无需同时清除CPA特异性抗体。
研究设计与样本
- 测定血清中CPA特异性抗体滴度,并评估其抑制血清介导铜绿假单胞菌 killing 的能力。
主要发现
- 患者血清IgG和IgA对CPA的应答分别有86%和69%升高。
- 69%的囊性纤维化患者定植了表达CPA的分离株。
- 仅1对血清-菌株显示补体抑制证据,该菌株CFP3A的CPA表达显著高于所有其他菌株。
- 针对CFP3A的补体介导 killing 被抗CPA抗体以滴度依赖方式抑制。
临床怎么用
- 在通过清除遮蔽抗体治疗多重耐药铜绿假单胞菌时,通常无需额外清除CPA特异性抗体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: People with cystic fibrosis (pwCF) are susceptible to chronic lung infections, particularly with Pseudomonas aeruginosa. During infection, a subset of patients develops cloaking antibodies specific to O-antigen lipopolysaccharide that impair complement-mediated bactericidal killing. These antibodies associate with worse disease, and their removal via plasmapheresis has been used as a successful treatment for multidrug-resistant P aeruginosa. Whether a similar mechanism of antibody-mediated serum resistance exists toward common polysaccharide antigen (CPA) lipopolysaccharide is unknown. METHODS: Forty-two serum samples and 63 matched P aeruginosa isolates were collected from pwCF. The titers of antibodies specific to CPA in patient sera were determined, and the ability of these antibodies to inhibit serum-mediated killing of P aeruginosa was assessed. RESULTS: Despite widespread anti-CPA antibodies, only 1 serum-strain pair showed evidence of complement inhibition. Patient serum IgG and IgA responses to CPA were elevated in 86% and 69% of sera, respectively. Furthermore, 69% of pwCF were colonized with CPA-expressing isolates. Despite the high prevalence of elevated anti-CPA antibodies, only 1 patient had antibodies capable of inhibiting complement killing of the cognate P aeruginosa. This isolate, CFP3A, had significantly higher expression of CPA than all other strains. Complement-mediated killing toward it was inhibited by anti-CPA antibodies in a titer-dependent manner. CONCLUSIONS: This investigation reveals that although antibody specific for CPA is prevalent in pwCF, it cannot inhibit complement killing of the majority of CPA-expressing strains. Thus, when Pseudomonas is treated by removal of cloaking antibodies, it is unlikely that CPA-specific antibodies will also need to be eliminated.
引用
- Monteith JN, Ledger EL, Chamoun MN, et al. Treatment of Pseudomonas by Removal of Cloaking Antibodies: Is Common Polysaccharide Antigen a Factor? J Infect Dis. 2026. PMID: 41493906. doi:10.1093/infdis/jiag002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。